Developing regions vs France: Proportion of the target population who received a 3rd dose of
Developing regions
66.0%
in 2024
France
96.0%
in 2024
Developing regions rank
12th
France rank
15th
Proportion of the target population who received a 3rd dose of over time
- Developing regions
- France
How they compare
France currently reports 96.0% against 66.0% in Developing regions, a difference of 30.0%.
That makes France's figure about 1.5 times Developing regions's.
Across all 15 years both countries report, France has been ahead every year.
Developing regions ranks 12th and France ranks 15th of 19 groups.
France has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Developing regions | France | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 28.4% | 90.5% | 62.1% | France |
| 2020s | 56.4% | 95.6% | 39.2% | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher proportion of the target population who received a 3rd dose of, Developing regions or France?
- France, at 96.0% against 66.0% in Developing regions as of 2024.
- What is the difference in proportion of the target population who received a 3rd dose of between Developing regions and France?
- 30.0%, with France ahead.
- How many years of comparable data are there for Developing regions and France?
- 15 years are reported by both, from 2010 to 2024.
- How do Developing regions and France rank globally for proportion of the target population who received a 3rd dose of?
- Developing regions ranks 12th and France ranks 15th of 19 groups.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Proportion of the target population who received a 3rd dose of pneumococcal conjugate (PCV3) vaccine (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.